Regulation of Cholesterol Metabolism in Liver: Link to NAFLD and Impact of n-3 PUFAs

Jin-Sik Bae, Ah-Reum Oh, Ji-Young Cha*
Laboratory of Cell Metabolism and Gene Regulation, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Korea

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease that affects one-third of adults in westernized countries. NAFLD represents a wide spectrum of hepatic alterations, ranging from simple triglyceride accumulation in the liver to steatohepatitis. Several pharmaceutical approaches to NAFLD management have been examined, but no particular treatment has been considered both safe and highly effective. Growing evidence reveal that supplemental fish oil, seal oil and purified n-3 fatty acids can reduce hepatic lipid content in NAFLD through extensive regulation by inhibiting lipogenesis, promoting fatty acid oxidation and suppressing inflammatory responses. Recently, the fat-1 transgenic mice capable of converting n-6 to n-3 polyunsaturated fatty acids (PUFAs) have been used to examine the effects of endogenous n-3 PUFAs on NAFLD. The increased n-3 PUFAs in fat-1 transgenic mice reduced diet-induced hyperlipidemia and fatty liver through induction of CYP7A1 expression and activation of cholesterol catabolism to bile acid. This article introduces the n-3 PUFAs, and addresses the evidence and mechanisms by which endogenously synthesized n-3 PUFAs or increased dietary n-3 PUFAs may ameliorate NAFLD.

Key Words: Cholesterol metabolism, Hepatic steatosis, Lipid metabolism, Non-alcoholic fatty liver disease, n-3 polyunsaturated fatty acids

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is characterized by pathological fat accumulation in hepatocytes in the absence of excessive alcohol consumption, which comprises a wide spectrum of liver disease ranging from steatosis to steatohepatitis, cirrhosis and even hepatocellular carcinoma. It is clear that NAFLD is strongly associated with insulin resistance, obesity, dyslipidemia and diabetes but its pathogenesis is not fully understood [1]. According to the “two hit” hypothesis, hepatic steatosis and insulin resistance occur first because of an increased uptake of lipids and/or decreased fatty acids oxidation, inadequate de novo synthesis of triglycerides, and/or decreased synthesis or secretion of very low density lipoproteins (VLDLs) in liver [2]. This induces a chronic inflammatory condition characterized by the release of pro-inflammatory cytokines and oxidative stress. Both of which are responsible of the “second hit”, which induces the progression from steatosis to more advanced stages of liver damage. This theory, however, should be revised since the increased ratio of saturated-to-unsaturated fatty acids within the liver directly induce hepatic inflammation and insulin resistance, which may worsen NAFLD progression [3].

Currently, the first-line treatment of NAFLD is based on diet and lifestyle modification. Studies of the dietary habits of NAFLD patients showed low intake of n-3 poly-
unsaturated fatty acids (PUFAs) and/or a lower relative concentration of n-3 PUFAs in tissues and blood [4-6]. Indeed, insufficient intake of n-3 PUFAs is associated with increased risk of NAFLD independent of traditional risk factors and data strongly support the detrimental role of high n-6/n-3 ratio on metabolic parameters [4]. Deficiency of n-3 PUFAs leads to hepatic steatosis and insulin resistance, whereas dietary supplementation of n-3 PUFAs appears to safely reduce nutritional hepatic steatosis in adults [7]. The present review discusses the potential mechanisms through which n-3 PUFAs may show its benefits in NAFLD, and the current data supporting its use.

**METABOLISM OF n-3 PUFAs**

Fatty acids, essential components of all cell membranes, play a number of key roles in metabolism such as being a major metabolic fuel (storage and transport energy), and the ligands for transcription factors. Although animals can synthesize saturated fatty acids and some monounsaturated fatty acids from carbon groups in carbohydrates and proteins, they lack the enzymes, desaturases, which are necessary to insert a cis double bond at the n-6 or the n-3 position of a fatty acid. Consequently, linoleic acid (LA, C18:2; n-6) and alpha-linolenic acid (ALA, C18:3; n-3) are essential nutrients that must be taken from food [8]. Human can synthesize long-chain n-6 PUFAs, such as arachidonic acid (AA; C20:4; n-6) from LA and long-chain n-3 PUFAs, such as eicosapentaenoic acid (EPA; C20:5; n-3) and docosahexaenoic acid (DHA; C22:6; n-3) from ALA (Fig. 1). However, EPA and DHA have to be obtained from diet because mammals inefficiently convert ALA to EPA and DHA [9]. n-3 PUFAs are enriched in fish oil, flaxseed and some nuts whereas n-6 PUFAs are found predominantly in grain and vegetable oil. It has been estimated that the ratio of n-6 to n-3 PUFAs in the diet of early humans was 1:1 [10], but the ratio in the typical Western diet is now almost 10:1 due to increased use of vegetable oils rich in LA as well as reduced fish consumption [11]. A lower intake in dietary sources of n-3 PUFAs seems to be associated with NAFLD [4,12]. In fact, patients with hepatic steatosis present a lower n-3/n-6 PUFA ratio in liver tissue biopsies, namely in phospholipids subfractions, and in red blood cells [5,6].

![Fig. 1. Metabolism of n-3 and n-6 polyunsaturated fatty acids (PUFAs). Linolenic acid (LA) and alpha-linolenic acid (ALA) are the parent PUFAs for n-6 and n-3, respectively. The fat-1 gene encodes an n-3 desaturase that converts n-6 to n-3 fatty acid.](image-url)
THE EFFECTS OF DIETARY n-3 PUFAs AND UNDERLYING MECHANISMS

Health benefits of dietary n-3 PUFAs include decrease of triglyceridemia and hepatic steatosis in human and rodent models of obesity. Indeed, n-3 PUFAs supplementation lessened the hepatic steatosis in ob/ob mice [13-16] and in rats fed a high-fat diet (HFD) [17,18]. In addition to improvement in hepatic steatosis, these rodent models had lowered plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels [14,19,20]. The lipid-lowering effect of n-3 PUFAs in rats fed high fat/cholesterol has been associated with the downregulation of de novo lipogenesis and upregulation of lipid oxidation.

Lipogenesis is thought to be regulated via the transcription factors carbohydrate response element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c), which are activated by glucose and insulin, respectively [21,22]. On the contrary, peroxisome proliferator activated receptor α (PPAR α) is a transcription factor known to decrease plasma lipids and induce enzymes and other proteins involved in lipid oxidation within the mitochondria, microsomes and peroxisomes [23]. The increased hepatic SREBP-1c/PPAR α ratio and steatosis are strongly correlated with insulin resistance and n-3 PUFA depletion in obese patients [24]. Administration of n-3 PUFAs to obese patients and NAFLD-prone rodents decreased the nuclear abundance of ChREBP/SREBP-1c while induced PPAR α in the liver [14,17]. Furthermore, the expression of ChREBP/SREBP-1c-dependent, glycolytic/lipogenic enzymes were reduced, while that of PPAR α-dependent, oxidative enzymes were increased by n-3 feeding [23,25].

Fish oil feeding is also associated with elevated concentration of adiponectin in the circulation and visceral adipose tissue [13,17,26]. Adiponectin, one of the insulin-sensitizing adipokines, has been shown to reduce hepatic lipids by activating fatty acid oxidation and inhibiting hepatic lipogenesis in liver [27,28]. Various pathological conditions are associated with lower plasma adiponectin concentration. Specifically, NAFLD patients have lower levels of adiponectin whereas fish oil supplementation to the obese increases adiponectin in most [29-31], but not all studies [32].

Besides the function on metabolic homeostasis, there is evidence from several studies that n-3 PUFAs have also shown the anti-inflammatory and anti-oxidant effects to protect the cells from ROS-induced damage [20,33]. Overall, these results suggest that n-3 PUFAs reduce hepatic lipids, markers of inflammation, and improve insulin sensitivity, all major events in NAFLD development and/or progression.

THE FAT-1 TRANSGENIC MICE

Although increasing the ratio of dietary n-3 to n-6 PUFAs might be beneficial in the prevention and treatment of dyslipidemia, obesity, insulin resistance, NAFLD and diabetes, it is difficult to ascertain the contribution of certain n-3 PUFAs per se, without the potential confounding effects of other dietary components. Since no pure n-3 and n-6 fatty acids are available, the major sources of the required n-3 and n-6 PUFAs are from fish oils and plant seed/vegetable oils, respectively. These two kinds of oils contain different bioactive compounds, such as saturated fatty acids, monounsaturated fatty acids, cholesterol, antioxidants, contaminants and other unidentified substances, that affect the study outcomes. Indeed, while it is generally accepted that fish oil improves the serum lipid profile, it is controversial whether dietary flaxseed oil has a similar effect [34]. Studying the effects of dietary n-3 PUFAs in the context of high fat feeding has proven to be rather complicated because incorporation of n-3 PUFAs into rodent diets often prevents weight gain [35].

Therefore it is ideal to develop a transgenic mouse capable of converting n-6 to n-3 PUFAs so that the results obtained in such an animal model will be more reliable and easy to interpret in terms of the effects of n-3 and n-6 PUFAs. As mentioned, n-3 PUFAs are not synthesized in mammals including humans. Kang et al. generated fat-1 transgenic (fat-1) mice expressing the Caenorhabditis elegans fat-1 gene encoding an n-3 fatty acid desaturase that converts n-6 PUFAs to n-3 PUFAs (Fig. 1) [36]. This allows production of two different FA profiles (low vs high n-6/n-3 ratios) in the fat-1 mice and wild-type littermates by using just a single diet, thus eliminating the potential diet variations. Hence, the fat-1 mice are valuable in vivo system for elucidating the role of n-3 PUFAs and the n-6/n-3 ratio.
in NAFLD development and progression.

**ENDOGENOUSLY SYNTHESIZED n-3 PUFA EFFECTS ON NAFLD**

Studies on fat-1 mice yielded interesting results including reduction of inflammation, bone loss, colitis, colon cancer, melanoma growth, invasiveness of lung cancer cells, and seizure susceptibility [37-42]. White et al. [43] reported that transgenic restoration of n-3 PUFAs in insulin target tissues improved resolution capacity and alleviated obesity-linked inflammation and insulin resistance in HFD-fed mice. The authors proposed that the endogenous n-3 PUFAs exerted their protective effects through their lipid oxygenation products, which reduced macrophage infiltration and inflammation in the expanding adipose tissue of obese mice. However, the hepatic lipid accumulation was not changed in both HFD-fed wild-type and fat-1 mice, showing different results from dietary n-3 PUFAs supplementation reversed hepatic steatosis in ob/ob mice [15].

We have recently reported that endogenously synthesized n-3 PUFAs could ameliorate HFD-induced fatty liver and hyperlipidemia in fat-1 mice, leading to significant attenuation of NAFLD and hepatic injury, as reflected by significant decreases in either triglyceride (TG) or liver enzymes, including AST and ALT [44]. Protection against hyperlipidemia in fat-1 mice was associated with significant upregulation of genes involved in cholesterol uptake (Ldlr), bile acid metabolism (Cyp7a1) or excretion (Abcg5 and Abcg8), and downregulation of Apoa4, a component of chylomicrons and HDL. These results suggested that endogenously synthesized n-3 PUFAs ameliorated fatty liver and hypercholesterolemia through modulating cholesterol and bile acid metabolism. Recently, cholesterol accumulation is proposed to participate to the pathogenesis of NAFLD and non-alcoholic steatohepatitis [45]. Moreover, patients with NAFLD also exhibited high hepatic-free cholesterol levels [45]. The sole pathways for hepatic cholesterol elimination are bile acid synthesis and cholesterol exported into the bile [46]. CYP7A1 is the rate-limiting enzyme in the bile acid synthetic pathway that converts cholesterol into bile acids in the liver. Recent studies have shown that transgenic mice overexpressing CYP7A1 were protected against HFD-induced hypercholesterolemia, obesity, and insulin resistance [47]. Moreover, the hepatic cholesterol transporters Abcg5 and Abcg8 were significantly induced in Cyp7a1-tg mice [47], as shown in fat-1 mice [44]. Therefore, the findings regarding to the regulation of Ldlr and Cyp7a by endogenous n-3 PUFAs paralleled its effects on circulating cholesterol, TG, and LDL cholesterol levels during HFD treatment and provided mechanistic evidence for decreased cholesterol accumulation and increased hepatic uptake of circulating LDL cholesterol.

**CONCLUSION**

The prevalence of NAFLD is increasing worldwide. Although simple steatosis is relatively benign and principally reversible, steatohepatitis is the progressive form of NAFLD and can develop cirrhosis, hepatic failure, and hepatocellular carcinoma. The only approved management of NAFLD is lifestyle modification including increased physical activity, dietary behaviors, and weight reduction. Therefore, an effective pharmacotherapy is required in NAFLD management. n-3 PUFAs have been suggested as a treatment for NAFLD. Dietary n-3 PUFAs reduce hepatic steatosis, inflammation and oxidative stress and improve insulin sensitivity. Studies on fat-1 mice revealed that endogenously synthesized n-3 PUFAs ameliorated fatty liver and hypercholesterolemia resulting from enhanced hepatic CYP7A1 expression. These findings underscore the importance of endogenous n-3 PUFAs to maintain whole-body bile acid homeostasis, which plays a key role in lipid, glucose, and energy homeostasis. To confirm the clinical relevance of the preventive effect of exogenous n-3 PUFAs on NAFLD, the physiological concentration of n-3 PUFAs required to produce similar effects on the fatty livers of fat-1 mice should be determined. For this purpose it will be helpful to investigate the concentrations of n-3 PUFAs in the liver after administration of various doses exogenous n-3 FAs in WT mice compared to fat-1 mice.

**ACKNOWLEDGEMENTS**

This work was supported by the Basic Science Research Program through the National Research Foundation of
Korea (NRF) funded by the Ministry of Education, Science and Technology [NRF-2012R1A1A3018738 to J-Y Cha].

REFERENCES

1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332:1519-23.
2. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114:842-5.
3. Gentile CL, Pagliassotti MJ. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 2008;19:567-76.
4. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, Oren R. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007;47: 11-7.
5. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Ponchiak J. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004;106:635-43.
6. Elizondo A, Araya J, Rodrigo R, Ponchiak J, Caendes A, Maluenda F, Diaz JC, Signorini C, Sgherri C, Comporti M, Videla LA. Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity (Silver Spring) 2007;15:24-31.
7. Pachikian BD, Essaghri A, Demoulin JB, Neyrinck AM, Catry E, De Backer FC, Dejeans N, Dewulf EM, Sohet FM, Portois L, Deldicque L, Molenendi-Coste O, Leclercq IA, Francaux M, Carpentier YA, et al. Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets. PLoS One 2011;6:e23365.
8. Das UN, Puskas LG. Transgenic fat-1 mouse as a model to study the pathophysiology of cardiovascular, neurological and psychiatric disorders. Lipids Health Dis 2009;8:61.
9. Ratnakumar WM, Galli C. Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Ann Nutr Metab 2009;55: 8-43.
10. Simopoulos AP, Leaf A, Salem N Jr. Workshop statement on the essentiality of and recommended dietary intakes for Omega-6 and Omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 2000;63:119-21.
11. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57.
12. Shapiro H, Tehilla M, Attal-Singer J, Bruck R, Luzzatti R, Singer P. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr 2011;30:6-19.
13. Gonzalez-Periz A, Horrillo R, Ferro N, Gronert K, Dong B, Moran-Salvador E, Titos E, Martinez-Clemente M, Lopez-Parra M, Arroyo V, Claría J. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009;23:1946-57.
14. Sekiya Y, Yahagi N, Matsuzaka T, Najima Y, Nakakaki M, Nagai R, Ishibashi S, Osuga Y, Yamada N, Shimano H. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003;38:1529-39.
15. Alwayn IP, Andersson C, Zauscher B, Gura K, Nose V, Puder M. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation 2005;79:606-8.
16. Kajikawa S, Harada T, Kawashima A, Imada K, Mizuguchi K. Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats. Dig Dis Sci 2010;55:631-41.
17. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, De Minics S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006;169:846-60.
18. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004;39:608-16.
19. El-Badry AM, Moritz W, Contaldo C, Tian Y, Graf R, Clavien PA. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology 2007;45:855-63.
20. Ishii H, Horie Y, Ohshima Y, Anezaki Y, Moritomi N, Dohmen T, Katoaoka E, Sato W, Goto T, Sasaki J, Sasaki T, Watanabe S, Suzuki A, Ohnishi H. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J Hepatol 2009;50:562-71.
21. Uyeda K, Yamashita H, Kikuchi T. Carbohydrate responsive element-binding protein (ChREBP): a key regulator of glucose metabolism and fat storage. Biochem Pharmacol 2002;63:2075-80.
22. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozocin-induced diabetes. Proc Natl Acad Sci USA 1999;96:13656-61.
23. Jump DB. N-3 polyunsaturated fatty acid regulation
of hepatic gene transcription. *Curr Opin Lipidol* 2008; 19:242-7.
24. Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Korn O, Maluenda F, Diaz JC, Rencoret G, Braghetto I, Castillo J, et al. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. *Biochim Biophys Acta* 2009;1792:1080-6.
25. Jump DB, Botolin D, Wang Y, Xu J, Demeure O, Christian B. Docosahexaenoic acid (DHA) and hepatic gene transcription. *Chem Phys Lipids* 2008;153:3-13.
26. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Scholmerich J, Bollheimer LC. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. *J Mol Endocrinol* 2006;36:485-501.
27. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). *Prog Lipid Res* 2009;48:1-26.
28. Awazawa M, Ueki K, Inabe K, Yamauchi T, Kaneko K, Okazaki Y, Bardeesy N, Ohnishi S, Nagai R, Kadowaki T. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. *Biochem Biophys Res Commun* 2009;382:51-6.
29. Kratz M, Swarbrick MM, Callahan HS, Matthys CC, Havel PJ, Weigle DS. Effect of dietary n-3 polyunsaturated fatty acids on plasma total and high-molecular-weight adiponectin concentrations in overweight to moderately obese men and women. *Am J Clin Nutr* 2008;87:347-53.
30. Itoh M, Suganami T, Nomura S, Inami N, Shouzu A, Omoto S, Kimura Y, Yuan X, Tanaka A, Kamei Y, Ogawa Y. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. *Arterioscler Thromb Vasc Biol* 2007;27:1918-25.
31. Krebs JD, Browning LM, McLean NK, Rothwell JL, Misra JD, Moore CS, Jebb SA. Additive benefits of long-chain n-3 polyunsaturated fatty acids in fat-1 transgenic mice endogenously synthesizing high levels of omega-3 polyunsaturated fatty acids. *Int J Obes (Lond)* 2006;30:1535-44.
32. Nomura S, Inami N, Shouzu A, Omoto S, Kimura Y, Takahashi N, Tanaka A, Urase F, Maeda Y, Ohtani H, Iwasaka T. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. *Platelets* 2009;20:16-22.
33. Broughton KS, Wade JW. Total fat and (n-3):(n-6) fat ratios influence eicosanoid production in mice. *The Journal of Nutrition* 2002;132:88-94.
34. Xu J, Yang W, Deng Q, Huang Q, Yang J, Huang F. Flaxseed oil and alpha-lipoic acid combination reduces atherosclerosis risk factors in rats fed a high-fat diet. *Lipids Health Dis* 2012;11:148.
35. Buckley JD, Howe PR. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. *Obes Rev* 2009;10:648-59.
36. Kang JX, Wang J, Wu L, Kang ZB. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. *Nature* 2004; 427:504.
37. Rahman M, Halade GV, Bhattacharya A, Fernandez G. The fat-1 transgene in mice increases antioxidant potential, reduces pro-inflammatory cytokine levels, and enhances PPAR-gamma and SIRT-1 expression on a calorie restricted diet. *Oxid Med Cell Longev* 2009;2:307-16.
38. Jia Q, Lupton JR, Smith R, Weeks BR, Callaway E, Davidson LA, Kim W, Fan YY, Yang P, Newman RA, Kang JX, McMurray DN, Chapkin RS. Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice. *Cancer Res* 2008;68:3985-91.
39. Bhattacharya A, Chandrasekar B, Rahman MM, Banu J, Kang JX, Fernandez G. Inhibition of inflammatory response in transgenic fat-1 mice on a calorie-restricted diet. *Biochim Biophys Acta* 2009;48:925-30.
40. Rahman MM, Bhattacharya A, Banu J, Kang JX, Fernandez G. Endogenous n-3 fatty acids protect ovarioctomy induced bone loss by attenuating osteocalcogenesis. *J Cell Mol Med* 2009;13:1833-44.
41. Taha AY, Huot FS, Reza-Lopez S, Prayitno NR, Kang JX, Burnham WM, Ma DW. Seizure resistance in fat-1 transgenic mice endogenously synthesizing high levels of omega-3 polyunsaturated fatty acids. *J Neurochem* 2008;105:380-8.
42. Mayer K, Kiessling A, Ott J, Schaefer MB, Hecker M, Henecke I, Schulz R, Gunther A, Wang J, Wu L, Roth J, Seeger W, Kang JX. Acute lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty acids. *Am J Respir Crit Care Med* 2009;179:474-83.
43. White PJ, Arita M, Taguchi R, Kang JX, Mareette A. Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. *Diabetes* 2010;59:3066-73.
44. Kim EH, Bae JS, Hahn KB, Cha JY. Endogenously synthesized n-3 polyunsaturated fatty acids in fat-1 mice ameliorate high-fat diet-induced non-alcoholic fatty liver disease. *Biochem Pharmacol* 2012;84:1359-65.
45. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. *Hepatology* 2007;46:1081-90.
46. Chiang JY. Bile acids: regulation of synthesis. *J Lipid
47. Li T, Owsley E, Matozel M, Hsu P, Novak CM, Chiang JY. Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. *Hepatology* 2010; 52:678-90.